Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care

The COVID-19 pandemic has brought to public attention significant vulnerabilities of older adults living in long-term care (LTC).1,2 This is due not only to the direct risk of COVID-19 and its potential complications but also the potential for inappropriate polypharmacy.3 Acute illnesses, of all types, commonly add medications to the profile and therefore increase the threat of drug-drug interactions (DDIs) and polypharmacy. Prescribers often fail to think of these issues when in the midst of treating an acute problem.